Together with a previously defined four-gene signature of aggressive tumours, including PTEN, SMAD4, CCND1 and SPP1 (ref. 16), determination of STAT3 and ARF expression could significantly improve the selection of patients with high risk PCa for personalized anti-cancer treatment. The gene discussed is CDKN2A; the disease is neoplasm.